Page 5 - Gland Pharma

After 100% gain since Nov, can the rally in Gland Pharma stock continue?

Gland's prospects remain strong, say analysts, as it has a robust pipeline of products with 50 pending Abbreviated New Drug Applications (ANDAs) and a healthy filing rate of 21 ANDAs in 9MFY21

Stocks to watch: Tata Motors, Airtel, Gland Pharma, HCL Tech, Orient Cement

Reliance Jio said it is constructing the largest international submarine cable system centred on India with global partners and submarine cable supplier Subcom to cater to increased data demand

Gland Pharma's Q4 consolidated net profit up 34% at Rs 260.4 crore

Drug firm Gland Pharma on Monday reported a 34 per cent rise in its consolidated net profit to Rs 260.4 crore for the fourth quarter ended March 2021, on account of robust sales

Gland Pharma hits new high; stock zooms 92% over issue price

The stock was trading higher for the fourth straight day, up 16 per cent during the period

Entrants' rally fizzles out: IPOs listed since Sept down 20% from peak

Shares of Antony Waste, Mrs Bectors Food, Chemcon Speciality and Burger King are down about 40 per cent each

Stelis Biopharma to make 200 mn doses of Russia's Sputnik V Covid vaccine

Stelis will commence supplies from September quarter of 2021 and will also continue to work with RDIF to provide additional supply volumes beyond the initial agreement

Gland Pharma rises after bagging deal to supply Russia's Covid-19 vaccine

Analysts upbeat about company's revenues, but say it will have to bump up its capacity quickly to meet the Russian order

India emerges global manufacturing hub for Covid-19 vaccine Sputnik V

Gland Pharma to make 252 mn doses, Hetero 100 mn doses, Strides may also join the fray

Gland Pharma inks pact to supply 252 mn doses of Sputnik V Covid vaccine

The production is expected to commence from the third quarter of 2021 for estimated delivery starting from the fourth quarter of 2021

New launches, market share gains to sustain Gland Pharma's sales trajectory

Earnings are expected to grow over 25 per cent over the next two years

Gland Pharma's growth trajectory to remain elevated in medium term

Margin expansion to support profits, clean regulatory track record to help sustain growth journey

Street signs: Mrs Bector's GMP, Gland Pharma on FPI red-flag list and more

If grey market activity is to be believed, despite the high acquisition price, HNIs will make money.

Why retail, HNI investors may be regretting giving Gland Pharma IPO a miss

Gland Pharma, promoted by China's Fosun, has extended its gains, is up 40 per cent since its listing

Pharma shares in focus; Divi's Labs hits new high, Gland Pharma zooms 20%

Dishman Carbogen Amcis, Ipca Lab, SPARC, Caplin Point Laboratories, Dr. Lal PathLabs and Granules India from the S&P BSE Healthcare index were up in the range of 4 per cent to 5 per cent on the BSE

Gland Pharma makes strong market debut on Friday, stock rises 21%

The post-listing market capitalisation for the company stands at Rs 29,848 crore, helping it break into the top 10 valuable pharma firms in the country

Gland Pharma makes decent debut, shares end at 21% premium vs issue price

The Rs 6,480-crore IPO of Gland Pharma managed to sail through solely on the back of institutional investor demand.

MARKETS: Financials lift indices; Sensex up 282 pts, Nifty ends at 12,859

All that happened in the markets today

Gland Pharma's grey market premium soars ahead of Friday's debut

The retail and HNI portion of the IPO were subscribed just 51 per cent and 24 per cent, respectively

Gland Pharma's Rs 6,480-cr IPO sails through on institutional support

Institutional portion sees 6.4x subscription; HNIs, retail investors give issue a miss

Gland Pharma's Rs 6,480-crore IPO subscribed 21% a day ahead of close

Offering received bids for 6.4 mn shares as against 30 mn on offer